Related Experiment Video
Updated: Mar 26, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation in Atrial Fibrillation
Yousif Ahmad1, Gregory Yh Lip2
1Honorary Research Fellow.
Insights
Patients with atrial fibrillation (AF) face high stroke risk, but oral anticoagulation prevents most events. New anticoagulants and risk tools improve AF management and patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) significantly increases thromboembolic risk, leading to severe strokes.
- Oral anticoagulation is crucial for preventing thromboembolic complications in AF patients.
- Warfarin, though effective, has limitations leading to underuse.
Purpose of the Study:
- To review advances in antithrombotic therapy for atrial fibrillation.
- To discuss new oral anticoagulants and improved risk stratification schemes.
- To highlight the importance of effective anticoagulation in managing AF.
Main Methods:
- Literature review of anticoagulation strategies for AF.
- Analysis of new oral anticoagulants and their benefits.
- Discussion of risk stratification tools for identifying patients needing anticoagulation.
Main Results:
- New oral anticoagulants offer alternatives to warfarin, overcoming its limitations.
- Improved risk stratification enables better patient selection for anticoagulation.
- Advances aim to enhance thromboprophylaxis efficacy and safety in AF.
Conclusions:
- Modern antithrombotic therapies and risk assessment tools are improving AF management.
- Increased use of effective anticoagulation is expected to lead to better patient outcomes.
- Growing experience with new agents will further optimize AF treatment.
Abstract:
Patients with atrial fibrillation (AF) are at increased thromboembolic risk, and they suffer more severe strokes with worse outcomes. Most thromboembolic complications of AF are eminently preventable with oral anticoagulation, and the increasing numbers of AF patients mean antithrombotic therapy is the most crucial management aspect of this common arrhythmia. Despite the proven efficacy of warfarin, a string of limitations have meant that it is underused by physicians and patients alike. This has prompted a search for new anticoagulants that could overcome many of the inconveniences of dose variability and anticoagulant monitoring associated with warfarin, but without sacrificing efficacy in thromboprophylaxis. The arrival of new oral anticoagulants has been complemented by improved risk stratification schemes, which permit clinicians to easily and reliably identify patients requiring anticoagulation and their bleeding risk. These advances in AF treatment will hopefully translate into improved outcomes for patients, especially as our experience with the new agents grows.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

